Lung (Small Cell) Cancer: S1400 (Hematology Oncology Associates)

S1400 - Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer


This study is for patients that have advanced squamous cell lung cancer and has two steps: the initial screening step where we will examine tumor tissue and the sub-study treatment step where patients will be assigned to a treatment sub-study that is chosen based on the screening results.

The purpose of the study screening step is to perform genetic tests on patient tumor samples for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign patients to a treatment sub-study that is chosen based on the results (genes and proteins called “biomarkers”) of this genetic testing on the patient's tumor sample.

The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Lung (Small Cell)
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Health Care Cancer Clinic - Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office